Business
Immunic to Participate in Investor and Scientific Conferences in March
NEW YORK, March 7, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small
About this update from Immunic, Inc.
[{"type":"text","content":"NEW YORK, March 7, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in March:\nMarch 11-13: Leerink Partners Global Biopharma Conference. Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, and Jessica Breu, Vice President Investor Relations and Communications, will participate in one-on-one investor meetings at this conference in Miami, FL.March 17-20: Frontiers in Medicinal Chemistry. Two abstracts have been accepted for poster presentations at this conference in Munich, Germany. The poster presentations will be accessible on the \"Events and Presentations\" section of Immunic's website at: https://ir.imux.com/events-and-presentations.Poster Title: Characterisation of Dual Nurr1 Activator/DHODH Inhibitor Vidofludimus Calcium and Development Towards a Nurr1 Selective Tool CompoundPresenting Author: Christian Gege, Ph.D., Head of Intellectual Property at ImmunicAbstract ID: 11632_36356Poster Board Number: P039Poster Title: Characterizing the Effects of NR4A Agonism in Neuroinflammation In VitroPresenting Author: Romy Busch, Department of Pharmacy, Center for Pharmaceutical Research, Ludwig-Maximilians-University of MunichAbstract ID: 11632_36404Poster Board Number: P072The posters will be presented during the whole conference. Poster sessions are planned as following:\nPoster session I: Sunday, March 17, 2024, 6:00 – 10:00 pm CETPoster session II: Monday, March 18, 2024, 5:00 – 7:00 pm CETMarch 25-28: 33rd Annual Meeting of the Society for Virology. Two abstracts have been accepted for poster and oral presentations at this conference in Vienna, Austria. The presentations will be accessible on the \"Events and Presentations\" section of Immunic's website at: https://ir.imux.com/events-and-presentations.Poster Presentation: Preclinical Development of Host-Directed Dual-Target Small Molecule Inhibitors as Broad-Spectrum AntiviralsPresenting Author: Alexandra Herrmann, Ph.D., Manager Translational Pharmacology, ImmunicAbstract ID Number: 107Program ID: P 078Poster Session: Antiviral Therapy and ResistanceDate: Monday, March 25, 2024Time: 1:00 pm CETAbstract Title: Characterization...